Targeting New Treatments for Sarcoma in the Arm or Leg

Recruiting · Phase 2 · Sarcoma and related conditions · New Jersey and New York

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at a new treatment for patients with sarcoma in their arms or legs. It combines the medicine pembrolizumab with local chemotherapy delivered directly to the affected limb. The goal is to see if this approach can safely delay the growth of the disease.

This is a Phase 2 trial, which means it is looking at how well this treatment works and how safe it is. The study is regulated by the FDA and aims to include around 30 participants.

Who can join

Patients aged 12 and older can join the study. It is open to both men and women with specific types of sarcoma that have not responded to standard treatments. The study team will check if you meet all the requirements before you can participate.

Conditions

Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma

Age group

All ages

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Everyone in this study will receive pembrolizumab and undergo a procedure called isolated limb infusion (ILI). ILI involves giving chemotherapy directly to the affected limb. This will happen after starting pembrolizumab. Participants will receive treatments every three weeks.